SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is attracting significant community attention due to its strategic focus on autonomous AI agent infrastructure and a high-profile partnership with Google Cloud. While some investors are actively accumulating the token as a long-term play on the AI narrative, others remain cautious, debating the impact of token supply dynamics and the broader volatility of the altcoin market.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending as investors rally behind its emergence as a governance token for the decentralized reinsurance market, driving significant community excitement following recent listings on major trading platforms. The conversation is heavily focused on its real-world utility in insurance and the potential for a sustained price run, with many participants actively discussing buy-in strategies and long-term holding prospects.

Chip

Chip is currently trending as a prominent AI infrastructure play, with the community actively debating its potential as a GPU-backed lending protocol versus concerns over volatility and insider selling. Investors are closely monitoring its performance as they weigh the project's real-world use case in financing AI hardware against the risks typical of early-stage, high-beta crypto assets.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is experiencing heightened market attention ahead of upcoming quarterly earnings as investors monitor the competitive landscape in its core HIV business and progress within its oncology portfolio. The community remains focused on recent acquisition-related activity and the company's ability to maintain its market dominance through new product pipeline developments.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant selling pressure as investors grapple with concerns over the Exact Sciences integration, potential litigation, and broader sector rotation out of defensive healthcare stocks. While the community is debating whether the stock represents a deep-value opportunity or a long-term trap, sentiment remains divided between those expecting a structural rebound from multi-year support levels and those anticipating further downside.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant community buzz following its inclusion in a massive multi-billion dollar missile defense contract, sparking optimism about its long-term potential in sovereign space defense. Investors are actively discussing the stock's transition toward high-margin data analytics and a path to profitability, though sentiment remains tempered by ongoing debates regarding the company's management and past volatility.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as market participants debate its long-term value, with recent discussions centered on institutional adoption news, protocol upgrades, and its competitive positioning against other DeFi lending platforms. Community sentiment remains split between long-term holders expressing conviction in the protocol's fundamentals and traders reacting to short-term price fluctuations and broader market volatility.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as investors digest the bank's role as a major underwriter for the highly anticipated SpaceX IPO and ongoing developments regarding the firm's expanding digital asset strategy, including crypto ETF filings. The community remains focused on the bank's strong institutional pipeline, its wealth management performance, and broader market impacts following the recent wave of IPO advisory activity.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is experiencing heightened market activity as investors weigh record-breaking contract wins against ongoing concerns regarding the federal government's long-term reliance on private detention facilities. The stock remains a focal point for the community as they actively debate the potential for future asset sales, the impact of shifting DHS immigration policies, and the implications of founder George Zoley's return to the CEO role.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid a mixture of speculative price predictions, community frustration over stalled progress with the CLARITY Act, and ongoing debates regarding Ripple's escrow unlock process and potential institutional adoption. Investors remain polarized, with some accumulating during dips based on long-term utility expectations while others express skepticism and bearish sentiment over recent price stagnation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Where Will TransMedics Group Stock Be in 10 Years?

Where Will TransMedics Group Stock Be in 10 Years...

TMDX Stock Rallies As Analyst Sees 77% Upside  — Here’s Why  

Equity

TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target. 


Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

TransMedics (NASDAQ: TMDX) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market rea...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass., May 21, 2026 ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a...

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference TransMedics to Present at the William Blair 46th Annual Growth Stock Conference PR Newswire ANDOVER, Mass., May 19...

TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group dropped their target price on TransMedics Group from $152.00 to $124.00 and set a 'buy' rating on the stock in a research report on Wednesday...

TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TD Cowen reduced their target price on shares of TransMedics Group from $190.00 to $120.00 and set a "buy" rating for the company in a report on Wednesday...

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Bearish Sentiment

Buying - this is temporary noise

Holding existing position

Selling / Trimming / Shorting

Watching from the sidelines

$TMDX is sliding after Stifel flagged a surge in "dry runs.". TransMedics investors are divided: is this a temporary operational blip or a structural crack in the growth story? Cast your vote below.

$TMDX sliding on &quot;dry run&quot; concerns - are you buying this dip?

Stocktwits

 sliding on "dry run" concerns - are you buying this dip?

Current Price	$68.86
Prev Close	$67.85
Open	$68.18
Dividend Yield	0.00%
50-Day Moving Average	$76.94
Beta	1.29
Avg. Volume	1.2M
PE Ratio	15.80

52-Week High	$156.00
52-Week Low	$60.11
Market Capitalization	$2.38B
EPS (Annual)	$4.87
Price to Book	4.82
Revenue Per Employee	$674,269.49

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMDXTransmedics Group Inc

Latest TMDX News